Peter Colville, a 60-year-old British property maintenance manager, died during a luxury boat excursion off the coast of Alanya, Turkey, on July 27. The incident occurred during the second swimming stop near Cleopatra Beach aboard the Legend Big Kral, a vessel marketed as a "luxury pirate ship" that offers entertainment, snorkeling, and foam parties. Colville was on holiday with ten family members, including his children and grandchildren, when he was found floating face-up and unresponsive in the water.

Fellow passengers discovered Colville unconscious and hauled him onto the deck, where they began administering CPR. According to eyewitness accounts from his daughter Nakita Colville and other travelers, the crew appeared "unbothered and clueless" during the emergency. Nakita reported that crew members "just stood there with their arms crossed" while guests attempted lifesaving measures, and a barman subsequently pronounced her father deceased before staff covered his body with a towel.

The handling of the situation after Colville's death has drawn sharp criticism from passengers. While the coastguard arrived to transport Colville's body to the hospital and his grieving family was escorted off the vessel, the boat's entertainment program continued. According to multiple accounts, crew members organized a foam party for the remaining distressed passengers shortly after the tragedy. TripAdvisor reviews from passengers on the same cruise described the crew's response as having "no proper procedures" and declared the treatment "nothing short of horrifying."

The cause of Colville's death remains unknown, with his family noting he was believed to be in good health prior to the incident. The Legend Big Kral, which reportedly carried approximately 600 passengers on the day of the tragedy, lists its capacity as 1,200 on TripAdvisor. The UK Maritime and Coastguard Agency guidelines state that pleasure cruises carrying more than 100 people should have specific safety equipment, though the application of these standards to Turkish excursion boats remains unclear as investigations continue.

Global medical technology company Convatec has announced plans to establish a new flagship research and development hub in Manchester as part of a £500 million investment in the United Kingdom. The FTSE100-listed firm, which specializes in products for chronic wounds, diabetes, urinary incontinence, and stomas, will relocate its R&D operations from Deeside to Bruntwood SciTech's CityLabs 4.0 facility, scheduled to open in 2027. This strategic move represents a significant commitment to the UK's life sciences sector at a time when several other pharmaceutical companies have been shifting investments overseas.

The new Manchester facility will become one of the largest centers in Convatec's global network, spanning 125,000 square feet across seven storeys in the £42 million CityLabs 4.0 building. Located on Hathersage Road facing the Manchester Royal Infirmary, St Mary's and Royal Manchester Children's Hospital, the state-of-the-art facility will focus on research in four key therapeutic areas: advanced wound care, ostomy care, continence care, and infusion care. The company cited Manchester's "vibrant life sciences ecosystem, which includes leading universities, hospitals, and research institutions" as the primary reason for selecting the location.

Approximately 200 staff will be employed at the new Manchester hub, with most positions transferring from Convatec's existing R&D operation in Deeside, North Wales, which has served as a major research center since 1996. The company emphasized that no redundancies are planned as a consequence of the relocation and that the Deeside manufacturing site will remain unaffected, continuing to employ around 400 workers. The new Manchester facility is approximately 50% larger than the current Deeside operation and has capacity for up to 250 employees, allowing for future expansion.

Convatec's investment comes as part of a broader $1 billion worldwide R&D commitment, with the UK portion representing nearly half of this global initiative. The company, which generated $2.3 billion in revenue last year, typically allocates approximately 5% of its annual revenue to research and development. The relocation to Manchester positions Convatec to leverage the city's concentration of medical research institutions, including neighboring organizations such as the University of Manchester NHS Foundation Trust, biotech company QIAGEN, and MAC Clinical Research, strengthening its pipeline of new products addressing unmet needs in chronic care.